<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101561693</journal-id>
<journal-id journal-id-type="pubmed-jr-id">39259</journal-id>
<journal-id journal-id-type="nlm-ta">Cancer Discov</journal-id>
<journal-id journal-id-type="iso-abbrev">Cancer Discov</journal-id>
<journal-title-group>
<journal-title>Cancer discovery</journal-title>
</journal-title-group>
<issn pub-type="ppub">2159-8274</issn>
<issn pub-type="epub">2159-8290</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26546296</article-id>
<article-id pub-id-type="pmc">4775099</article-id>
<article-id pub-id-type="doi">10.1158/2159-8290.CD-15-0341</article-id>
<article-id pub-id-type="manuscript">NIHMS737318</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>MECP2</italic> Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism that Mimics the Role of Activated RAS in Malignancy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Neupane</surname>
<given-names>Manish</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Clark</surname>
<given-names>Allison P.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Landini</surname>
<given-names>Serena</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Birkbak</surname>
<given-names>Nicolai J.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eklund</surname>
<given-names>Aron C.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lim</surname>
<given-names>Elgene</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Culhane</surname>
<given-names>Aedin C.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Barry</surname>
<given-names>William T.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schumacher</surname>
<given-names>Steven E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beroukhim</surname>
<given-names>Rameen</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Szallasi</surname>
<given-names>Zoltan</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vidal</surname>
<given-names>Marc</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hill</surname>
<given-names>David E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Silver</surname>
<given-names>Daniel P.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA</aff>
<aff id="A2"><label>2</label>Depatment of Medicine, Harvard Medical School, Boston, MA 02115, USA</aff>
<aff id="A3"><label>3</label>Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, 2800 Kgs, Lyngby, Denmark</aff>
<aff id="A4"><label>4</label>The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia</aff>
<aff id="A5"><label>5</label>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA</aff>
<aff id="A6"><label>6</label>Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA</aff>
<aff id="A7"><label>7</label>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA</aff>
<aff id="A8"><label>8</label>Children's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, and Harvard Medical School, Boston, MA 02115</aff>
<aff id="A9"><label>9</label>Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA 02115, USA</aff>
<aff id="A10"><label>10</label>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA</aff>
<author-notes>
<corresp id="cor1"><label>*</label><bold>Corresponding author:</bold> Daniel P. Silver, Dana-Farber Cancer Institute, Smith Building, Room 868b, 450 Brookline Ave, Boston, MA 02215. Phone: 617-582-8485; Fax: 617-632-4381; <email>Daniel_Silver@dfci.harvard.edu</email></corresp>
<fn fn-type="conflict" id="FN1">
<p id="P48"><bold>Disclosure of Potential Conflicts of Interest:</bold> MN, DEH, and DPS are inventors on a patent held by the Dana-Farber Cancer Institute related to this study.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>25</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2016</year>
</pub-date>
<volume>6</volume>
<issue>1</issue>
<fpage>45</fpage>
<lpage>58</lpage>
<!--elocation-id from pubmed: 10.1158/2159-8290.CD-15-0341-->
<abstract>
<p id="P1">An unbiased genome-scale screen for unmutated genes that drive cancer growth when overexpressed identified <italic>MECP2</italic> as a novel oncogene. <italic>MECP2</italic> resides in a region of the X-chromosome that is significantly amplified across 18% of cancers, and many cancer cell lines have amplified, overexpressed <italic>MECP2</italic> and are dependent on <italic>MECP2</italic> expression for growth. <italic>MECP2</italic> copy number gain and <italic>RAS</italic> family member alterations are mutually exclusive in several cancer types. The <italic>MECP2</italic> splicing isoforms activate the major growth factor pathways targeted by activated RAS, the MAPK and PI3K pathways. <italic>MECP2</italic> rescued the growth of a <italic>KRAS</italic><sup>G12C</sup>-addicted cell line after <italic>KRAS</italic> down-regulation, and activated <italic>KRAS</italic> rescues the growth of an <italic>MECP2</italic>-addicted cell line after <italic>MECP2</italic> downregulation. MECP2 binding to the epigenetic modification 5-hydroxymethylcytosine is required for efficient transformation. These observations suggest that <italic>MECP2</italic> is a commonly amplified oncogene with an unusual epigenetic mode of action.</p>
</abstract>
<kwd-group>
<kwd>MECP2</kwd>
<kwd>RAS</kwd>
<kwd>oncogene</kwd>
<kwd>gene amplification</kwd>
<kwd>epigenetic therapy</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>